A. R. Hernández Salgado, C. Gallardo Pérez, J. M. García Cruz, M. Cruz Ramírez
Abstract
Arthropathy represents one of the most debilitating complications in individuals with congenital bleeding disorders, significantly impairing quality of life due to chronic pain and persistent joint inflammation. This pilot study explored the use of ozonated platelet-rich plasma (PRP-O₃) as a regenerative and anti-inflammatory therapeutic alternative. Five patients with various types and severities of hemophilia, and one patient with Von Willebrand disease, received intra-articular PRP-O₃ injections. Preliminary clinical outcomes indicated significant improvement in inflammatory symptoms and pain perception, with no complications or adverse events reported.
These findings suggest that PRP-O₃ may represent a safe, costeffective, outpatient therapeutic option for the complementary management of hemophilic arthropathy, encouraging a more integrative and less invasive approach. Controlled clinical trials are recommended to confirm its efficacy and to establish standardized protocols.
